Understand the source comparison
Comparison: Peptides for Mold Illness vs Standard CIRS Interventions
Thymosin Alpha-1 Restores regulatory T-cell differentiation, reduces TGF-beta-1-driven inflammation 8–12 weeks Does not clear mycotoxins; requires environmental remediation first First-line immune modulator for CIRS. Addresses root dysregulation, not symptoms
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Thymosin Alpha-1
- Restores regulatory T-cell differentiation, reduces TGF-beta-1-driven inflammation
- 8–12 weeks
- Does not clear mycotoxins; requires environmental remediation first
- First-line immune modulator for CIRS. Addresses root dysregulation, not symptoms
- BPC-157
- Repairs intestinal tight junctions, reduces gut-derived endotoxemia
- 4–6 weeks
- Short half-life requires daily dosing; oral bioavailability lower than subcutaneous
- Essential for patients with confirmed leaky gut or elevated LPS markers
- Cholestyramine (Standard CIRS Protocol)
- Binds mycotoxins in GI tract, prevents reabsorption
- 2–4 weeks for initial clearance, 4–6 months for full effect
- Does not address immune dysregulation; compliance difficult due to GI side effects
- Foundational toxin binder. Must precede peptide protocols
- VIP Nasal Spray (Standard CIRS Protocol)
- Reduces inflammatory cytokines (IL-6, TNF-alpha), restores hypothalamic-pituitary axis
- 6–8 weeks
- Expensive, requires compounding pharmacy, not always tolerated
- Effective for neuroinflammation but does not repair gut barrier or modulate Tregs
- Epithalon
- Activates telomerase, reduces oxidative stress, supports cellular regeneration
- 12–16 weeks
- Mechanism less specific to mold illness; best as adjunct, not primary intervention
- Useful for patients with severe fatigue and mitochondrial dysfunction